115,159 Shares in Boston Scientific Corporation $BSX Acquired by First Nebraska Trust Co

First Nebraska Trust Co bought a new stake in Boston Scientific Corporation (NYSE:BSX) during the second quarter, Holdings Channel.com reports. The fund bought 115,159 shares of the medical equipment provider’s stock, valued at approximately $4,915,000.

Other hedge funds have also bought and sold shares of the company. Bank of Nova Scotia bought a new position in shares of Boston Scientific in the 2nd quarter worth $56,496,000. Kirtland Hills Capital Management LLC purchased a new position in Boston Scientific in the second quarter worth $416,000. Elevation Point Wealth Partners LLC purchased a new position in Boston Scientific in the second quarter worth $1,314,000. Alta Advisers Ltd bought a new position in Boston Scientific in the second quarter valued at $247,000. Finally, Daiichi Life Insurance Co. Ltd. bought a new position in Boston Scientific in the second quarter valued at $1,551,000. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Michael F. Mahoney purchased 186,240 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward J. Ludwig purchased 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 194,522 shares of company stock valued at $9,385,210 over the last three months. 0.34% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on BSX shares. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Leerink Partners set a $60.00 price objective on Boston Scientific in a research report on Thursday, July 30th. Truist Financial decreased their price objective on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Finally, Barclays dropped their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research report on Thursday, May 28th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Price Performance

BSX opened at $50.39 on Friday. The stock’s 50 day simple moving average is $46.34 and its 200 day simple moving average is $57.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The firm has a market cap of $73.03 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the previous year, the firm earned $0.75 EPS. The business’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has initiated a stock buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.